NASDAQ:MRNA (Moderna)
About MRNA
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna (NASDAQ: MRNA) Latest News
Investing Articles
Up 14% yesterday, is it the end for this train wreck in my Stocks and Shares ISA?
Investing Articles
This S&P 500 stock could surge 55% in just 12 months, according to experts
Investing Articles
These FTSE 100 and Nasdaq stocks are stinking out my ISA! Should I dump them?
Investing Articles
2 growth shares stinking out my Stocks and Shares ISA in 2025!
Investing Articles
Moderna’s meant to be a red-hot growth stock. What on earth’s gone wrong?
Investing Articles
1 ISA mistake to avoid in 2025
Investing Articles
Down 87%, is this once-famous stock set to explode like the Rolls-Royce share price?
Investing Articles
1 exciting growth stock to buy for the long run in June
Investing Articles
1 intriguing growth stock that could send Scottish Mortgage shares above £10
Investing Articles
7 shares that Fools have been buying!
Investing Articles
After ChatGPT and Temu, what could be the biggest 2024 stock market winners?
Investing Articles
2 growth stocks I’d buy for the artificial intelligence (AI) revolution in 2024
1❯